When it comes to research at Servier, we are driven by our One Innovation Engine, a strategy which aims to accelerate the development and delivery of potential treatments to patients. One way Servier does this is through supporting both local and global startups through the Golden Ticket program, FAST Discovery Award, and other initiatives. Learn more about the winners of these programs: https://ow.ly/GLyH50TAl9U
About us
Servier is a privately held international pharmaceutical company headquartered in France with a passion for innovation that has improved patients’ lives around the world. With $4.7 billion in annual sales Servier operates in almost 150 countries worldwide across five therapeutic categories including oncology, cardiovascular, immuno-inflammatory, neuroscience and diabetes. Servier is founded on the principle of serving and governed by an independent non-profit foundation. With this unique operating model, the company can be deliberate about putting patients ahead of profits. In fact, Servier re-invests 25 percent of revenue into research and development each year. Servier is committed to therapeutic progress to serve patient needs and strives to provide future generations with a world where quality healthcare is available and accessible to all. See our community guidelines here: https://www.servier.us/community-guidelines To report a suspected adverse event with a Servier product, please visit: https://www.servier.us/contact-us
- Website
-
https://www.servier.us/
External link for Servier Pharmaceuticals
- Industry
- Pharmaceutical Manufacturing
- Company size
- 201-500 employees
- Headquarters
- Boston , MA
- Type
- Nonprofit
Locations
-
Primary
200 Pier Four Boulevard
Boston , MA 02210, US
Employees at Servier Pharmaceuticals
Updates
-
It was a perfect day for our annual golf outing! We had a fantastic mix of friendly competition, networking, and fun. Thank you to everyone who made this such a memorable event. Learn more about our unique people-first culture and see open roles here: https://ow.ly/jtNy50TAGpi
-
At Servier, we come together to recognize #ChildhoodCancerAwarenessMonth and the profound impact it has on children, families, caretakers and healthcare providers. At today’s Lunch & Learn we had a guest who shared their experience with childhood cancer with Servier employees. It was a profound and eye-opening opportunity for everyone who got to listen. For more on Servier’s work with patient services click the link here: https://ow.ly/c0qQ50TeQHr
-
At Servier, we are proud to continue pioneering the science of IDH inhibition. Learn more about IDH mutations in glioma from our Senior Director and Head of Biochemistry, Stefan Gross. https://ow.ly/MzKi50SWlzz
-
#ICYMI: Servier is expanding their neuroscience focused partnership with Aitia. This cooperation aims to leverage Aitia’s AI technology to advance scientific research. For more click here: https://ow.ly/h6zh50Tb9M7 #MovedByScience
-
This September, we join the global community in recognizing Blood Cancer Awareness Month. At Servier, we are committed to advancing research supporting patients and spreading awareness about blood cancers such as Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML). Learn more here: https://ow.ly/ktGL50Tb9Gx
-
Because the presence of IDH mutations in acute myeloid leukemia (AML) can impact a patient’s prognosis and potential treatment plan, molecular profiling is critical to inform next steps. Learn more here: https://ow.ly/7J7750SWlO5
-
For people living with acute lymphoblastic leukemia (ALL), knowledge is power. Know the signs, symptoms, and risk factors: https://ow.ly/LniN50SXOFl